Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

Leukemia & Lymphoma
Massimo OffidaniAntonio Palumbo

Abstract

The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM). Panobinostat is a potent oral pan-deacetylase inhibitor (pan-DACi). In preclinical and clinical studies, panobinostat showed good anti-myeloma activity in combination with several agents. This phase II study evaluated the combination of a fixed dose of MPT with escalating doses of panobinostat (three times weekly for 3 weeks, followed by a 9-day rest period) in relapsed/refractory MM. We used a two-stage design to determine whether the combination was safe and effective. At least a partial response was observed in 38.5% of patients. The maximum tolerated dose of panobinostat in combination with MPT could not be determined due to the high rate of dose-limiting toxicities experienced with panobinostat at doses of 10 and 15 mg. The most common grade 3/4 adverse events were neutropenia (71%) and thrombocytopenia (35.5%). In conclusion, MPT in combination with panobinostat three times weekly for 3 weeks followed by a 9-day rest period is not well tolerated in patients with relapsed/refractory MM. Future studies should evaluate alternative dose...Continue Reading

References

Mar 8, 2006·European Journal of Haematology·Antonio PalumboMario Boccadoro
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew A Lane, Bruce A Chabner

❮ Previous
Next ❯

Citations

Aug 27, 2013·Current Hematologic Malignancy Reports·Jason P Meadows, Tomer M Mark
Mar 19, 2013·Marine Drugs·Ying-Qing Wang, Ze-Hong Miao
May 16, 2014·Leukemia Research and Treatment·Pilar de la PuenteAbdel Kareem Azab
May 9, 2014·Epigenomics·Charlotte PawlynGareth J Morgan
May 3, 2014·Blood Cancer Journal·K DimopoulosK Grønbæk
Apr 26, 2013·Leukemia & Lymphoma·Roman HajekMeletios Dimopoulos
Nov 21, 2014·Expert Review of Hematology·Edward N LibbyWilliam Ira Bensinger
Jun 19, 2013·Expert Opinion on Biological Therapy·Sonia Vallet, Klaus Podar
Mar 13, 2012·Expert Opinion on Investigational Drugs·Paola NeriSagar Lonial
Jan 31, 2016·Targeted Oncology·Sarah L Greig
Apr 22, 2016·International Journal of Hematology·Takeshi HaradaKenneth C Anderson
Apr 4, 2015·Drugs·Karly P Garnock-Jones
Aug 25, 2015·Cancer Treatment Reviews·Meletios A DimopoulosAntonio Palumbo
Jun 24, 2016·Journal of Clinical and Experimental Hematopathology : JCEH·Masahiro Kizaki, Takayuki Tabayashi
Dec 4, 2014·Therapeutic Advances in Hematology·Claudia V Andreu-Vieyra, James R Berenson
May 10, 2019·Expert Opinion on Drug Safety·Guldane Cengiz Seval, Meral Beksac
May 11, 2021·British Journal of Clinical Pharmacology·Andrey D BondarevHelgi B Schiöth
Aug 4, 2021·Clinical Lymphoma, Myeloma & Leukemia·Jesus G BerdejaAjai Chari

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.